Trans Genic Inc. (2342) AI Stock Analysis

• Market Cap: ¥2.60B
• Dividend Yield: 1.95%
• Average Volume (3M): 74.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.46
• Revenue Growth: 3.46%
• EPS Growth: 59.89%
• Country: JP
• Employees: 236
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): -47.97
• Shares Outstanding: 16,999,142
• 10 Day Avg. Volume: 34,150
• 30 Day Avg. Volume: 74,030
• PEG Ratio: 0.11
• Price to Book (P/B): 0.93
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: ―

The overall score reflects significant financial challenges, particularly in profitability and cash flow, which are critical for long-term sustainability. Technical indicators are neutral, providing no strong momentum signals. The valuation metrics raise concerns, especially with a negative P/E ratio, indicating a need for improved financial performance to attract investors.

Trans Genic Inc. Business Overview & Revenue Model

Company Description

Trans Genic Inc. (2342) is a biotechnology company specializing in genetic engineering and synthetic biology solutions. The company operates in the healthcare and agriculture sectors, providing innovative products and services that enhance genetic traits for improved health outcomes and agricultural productivity. Its core offerings include genetically modified organisms (GMOs), gene editing services, and bioengineering tools designed to optimize biological processes and traits.

How the Company Makes Money

Trans Genic Inc. generates revenue through the sale of its genetically modified organisms and gene editing services to healthcare providers, pharmaceutical companies, and agricultural businesses. Key revenue streams include licensing agreements for its proprietary genetic technologies, direct sales of engineered organisms, and service contracts for custom gene editing projects. Significant partnerships with leading pharmaceutical and agricultural firms contribute to its earnings by leveraging collaborative research and development initiatives. Additionally, the company benefits from government grants and subsidies aimed at advancing genetic research and innovation.

Trans Genic Inc. Financial Statement Overview

Summary

Trans Genic Inc. faces significant financial challenges, particularly in maintaining profitability and cash flow generation. While the balance sheet is reasonably strong with a solid equity ratio and manageable leverage, the company struggles with operational efficiency and liquidity challenges.

Income Statement

Trans Genic Inc. has demonstrated volatile revenue growth with a recent decline in revenue from its peak in 2022. Margins have been pressured, with TTM figures showing a negative net profit margin of -1.89% and a gross profit margin of 17.44%. The EBIT and EBITDA margins have shown significant deterioration, indicating challenges in operational efficiency. Despite these challenges, the company has previously shown strong revenue growth in fiscal years leading up to 2022.

Balance Sheet

The balance sheet remains relatively strong with an equity ratio of 53.23% in TTM, indicating a solid capital structure. The debt-to-equity ratio is at 0.45, showing manageable leverage. However, the declining stockholders' equity and increased total debt over recent periods suggest potential risk factors. Historical ROE figures indicate varying profitability with recent declines.

Cash Flow

Cash flow metrics show concerning trends with negative free cash flow in recent periods, and free cash flow has been volatile. The operating cash flow to net income ratio has been negatively impacted recently, highlighting cash generation issues. These trends indicate potential liquidity challenges moving forward.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
13.15B	13.08B	11.43B	12.58B	11.05B	11.05B
	Gross Profit
2.29B	2.25B	1.99B	3.84B	2.78B	1.78B
	EBIT
-88.83M	89.44M	-25.15M	1.84B	893.20M	174.00M
	EBITDA
51.34M	240.95M	-119.83M	3.02B	975.06M	2.42M
	Net Income Common Stockholders
-248.60M	4.08M	-409.67M	1.88B	546.29M	-440.00M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.25B	2.48B	3.46B	4.62B	3.03B	329.54M
	Total Assets
10.45B	9.81B	10.67B	10.44B	8.92B	7.57B
	Total Debt
2.52B	2.26B	2.42B	1.82B	2.00B	1.76B
	Net Debt
272.00M	-221.17M	-1.04B	-2.80B	-1.03B	1.63B
	Total Liabilities
4.80B	3.81B	4.55B	3.80B	3.88B	3.15B
	Stockholders Equity
5.56B	5.89B	6.02B	6.53B	4.92B	4.42B
Cash Flow		Free Cash Flow
0.00	-658.12M	-1.74B	1.26B	1.08B	-276.00M
	Operating Cash Flow
0.00	-392.45M	-1.43B	1.79B	1.22B	-20.00M
	Investing Cash Flow
0.00	-280.93M	-216.02M	981.87M	48.43M	-318.00M
	Financing Cash Flow
0.00	-342.69M	484.98M	-1.18B	10.04M	666.00M

Trans Genic Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 154.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2342, the sentiment is Negative. The current price of 154 is below the 20-day moving average (MA) of 157.40, below the 50-day MA of 167.34, and below the 200-day MA of 195.94, indicating a bearish trend. The MACD of -4.18 indicates Negative momentum. The RSI at 39.59 is Neutral, neither overbought nor oversold. The STOCH value of 44.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2342.

Trans Genic Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4519	79 Outperform	$12.26T	29.92	22.80%	1.53%	17.96%	25.65%
4578	77 Outperform	$3.83T	11.14	13.46%	1.65%	14.52%	156.70%
4503	71 Outperform	$2.50T	48.98	3.22%	5.08%	19.25%	294.48%
4523	69 Neutral	¥1.14T	24.61	5.34%	3.95%	6.42%	10.82%
Sector *	54 Neutral	$5.34B	3.27	-45.10%	3.30%	16.80%	0.02%
2342	50 Neutral	¥2.60B	―		1.95%	3.46%	59.89%
4563	44 Neutral	$23.22B	―	-193.61%	―	179.79%	-204.13%